chr10-53866870-GA-G
Position:
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP6_Very_StrongBS1BS2
The NM_001384140.1(PCDH15):c.3502-14delT variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00123 in 1,480,142 control chromosomes in the GnomAD database, including 12 homozygotes. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.0028 ( 1 hom., cov: 22)
Exomes 𝑓: 0.0011 ( 11 hom. )
Consequence
PCDH15
NM_001384140.1 intron
NM_001384140.1 intron
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.936
Genes affected
PCDH15 (HGNC:14674): (protocadherin related 15) This gene is a member of the cadherin superfamily. Family members encode integral membrane proteins that mediate calcium-dependent cell-cell adhesion. It plays an essential role in maintenance of normal retinal and cochlear function. Mutations in this gene result in hearing loss and Usher Syndrome Type IF (USH1F). Extensive alternative splicing resulting in multiple isoforms has been observed in the mouse ortholog. Similar alternatively spliced transcripts are inferred to occur in human, and additional variants are likely to occur. [provided by RefSeq, Dec 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -16 ACMG points.
BP6
Variant 10-53866870-GA-G is Benign according to our data. Variant chr10-53866870-GA-G is described in ClinVar as [Benign]. Clinvar id is 179543.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr10-53866870-GA-G is described in Lovd as [Benign].
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00277 (415/150054) while in subpopulation AFR AF= 0.00802 (329/41008). AF 95% confidence interval is 0.00731. There are 1 homozygotes in gnomad4. There are 203 alleles in male gnomad4 subpopulation. Median coverage is 22. This position pass quality control queck.
BS2
High Homozygotes in GnomAdExome4 at 11 AR,Digenic gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCDH15 | NM_033056.4 | c.3502-14delT | intron_variant | ENST00000320301.11 | NP_149045.3 | |||
PCDH15 | NM_001384140.1 | c.3502-14delT | intron_variant | ENST00000644397.2 | NP_001371069.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCDH15 | ENST00000320301.11 | c.3502-14delT | intron_variant | 1 | NM_033056.4 | ENSP00000322604.6 | ||||
PCDH15 | ENST00000644397.2 | c.3502-14delT | intron_variant | NM_001384140.1 | ENSP00000495195.1 |
Frequencies
GnomAD3 genomes AF: 0.00276 AC: 414AN: 149950Hom.: 1 Cov.: 22
GnomAD3 genomes
AF:
AC:
414
AN:
149950
Hom.:
Cov.:
22
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00189 AC: 439AN: 232130Hom.: 4 AF XY: 0.00204 AC XY: 257AN XY: 125860
GnomAD3 exomes
AF:
AC:
439
AN:
232130
Hom.:
AF XY:
AC XY:
257
AN XY:
125860
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00106 AC: 1404AN: 1330088Hom.: 11 Cov.: 23 AF XY: 0.00122 AC XY: 815AN XY: 668006
GnomAD4 exome
AF:
AC:
1404
AN:
1330088
Hom.:
Cov.:
23
AF XY:
AC XY:
815
AN XY:
668006
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00277 AC: 415AN: 150054Hom.: 1 Cov.: 22 AF XY: 0.00278 AC XY: 203AN XY: 73118
GnomAD4 genome
AF:
AC:
415
AN:
150054
Hom.:
Cov.:
22
AF XY:
AC XY:
203
AN XY:
73118
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 28, 2014 | 3502-14delT in intron 26 of PCDH15: This variant is not expected to have clinic al significance because it is not predicted to alter splicing and has been ident ified in 0.6% (46/8254) European American chromosomes and in 1.2% (53/4264) Afri can American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.wa shington.edu; dbSNP rs5785023). - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 25, 2020 | Variant summary: PCDH15 c.3502-14delT alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0019 in 232130 control chromosomes, predominantly at a frequency of 0.0087 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 2.8 fold of the estimated maximal expected allele frequency for a pathogenic variant in PCDH15 causing Usher Syndrome Type 1F phenotype (0.0032), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. To our knowledge, no occurrence of c.3502-14delT in individuals affected with Usher Syndrome Type 1F and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as benign. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at